Literature DB >> 9620234

Advances in treatment with intensity-modulated conformal radiotherapy.

S Webb1.   

Abstract

The modern practice of radiotherapy centres on the development of conformal radiotherapy, techniques to ensure the high-dose volume is tightly wrapped around the diseased tissue and excluded as far as possible from adjacent normal structures. The development of conformal radiotherapy is a chain of processes involving treatment planning, development of new methods to deliver radiation, verification of the accuracy of radiation delivery and improvement of biological outcome. This is an enormous field of activity. This invited review paper summarises some of the main elements of progress towards implementing intensity-modulated conformal radiotherapy. This is the newest and most exciting development and, when achieved clinically, will lead to a quantum leap in tumour control probability with a fixed level of normal tissue damage.

Entities:  

Mesh:

Year:  1998        PMID: 9620234     DOI: 10.1177/030089169808400206

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  3 in total

Review 1.  Volumetric modulated arc therapy: a review of current literature and clinical use in practice.

Authors:  M Teoh; C H Clark; K Wood; S Whitaker; A Nisbet
Journal:  Br J Radiol       Date:  2011-11       Impact factor: 3.039

2.  A pilot prospective feasibility study of organ-at-risk definition using Target Contour Testing/Instructional Computer Software (TaCTICS), a training and evaluation platform for radiotherapy target delineation.

Authors:  Jayashree Kalpathy-Cramer; Steven D Bedrick; Kelly Boccia; Clifton D Fuller
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

3.  SUPR-3D: A randomized phase iii trial comparing simple unplanned palliative radiotherapy versus 3d conformal radiotherapy for patients with bone metastases: study protocol.

Authors:  Robert Olson; Roel Schlijper; Nick Chng; Quinn Matthews; Marco Arimare; Lindsay Mathews; Fred Hsu; Tanya Berrang; Alexander Louie; Benjamin Mou; Boris Valev; Joanna Laba; David Palma; Devin Schellenberg; Shilo Lefresne
Journal:  BMC Cancer       Date:  2019-10-28       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.